Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
innovaTV 301: Tisotumab vedotin vs chemotherapy in recurrent or metastatic cervical cancer
jRCT2011210028Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of tisotumab vedotin in Cervical Cancer (CC) (2 arms), sponsored by Pfizer. Primary endpoint: Overall survival. Started Oct 2021; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2011210028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210028.